PRESS RELEASE
Flormidabìl: the first Probiotic in the Polifarma portfolio arrives
Polifarma expands its market presence in the Gastroenterology area with the purchase of the entire Flormidabìl range
Rome, 11 January 2023 – Polifarma, azienda farmaceutica italiana fondata nel 1919, annuncia l’acquisto di Flormidabìl da Sandoz AG, integratore alimentare a base di fermenti lattici utile in caso di alterazioni della flora batterica intestinale, che si aggiunge al portfolio prodotti in area Gastro composta da farmaci e integratori alimentari.
This is the first entry of a probiotic into Polifarma. Flormidabìl has an exclusive multi-strain formulation, up to a maximum of 100MLD of live lactic ferments at expiry.
It has already been elected product of the year twice, with a range close to patient needs, and is currently among the top ten probiotics sold in Italy.
Polifarma will continue the work on enhancing the brand, in continuity with what Sandoz AG has built, and this operation confirms both the company's plan aimed at strengthening its influence in areas of the market considered strategic, and the constant investment in the product portfolio. Polifarma's programs also include the will to launch Flormidabìl outside national borders. Italy is the third largest market in the world for probiotics. According, in fact, to the data of IPA Europe – International Probiotics Association, il mercato europeo degli integratori probiotici è stato valutato 1.464 milioni di euro nel 2021, quasi il 25% del valore globale, e con un tasso di crescita previsto del 3% per il periodo 2021-2026. L’Italia conta 560,5 milioni di euro di vendite di integratori probiotici nel 2021 con una previsione di crescita del 5% per il periodo 2021-2026.
To announce the new purchase is theCEO of Polifarma, Andrea Bracci, who comments as follows: “Another important result that closes a year of extraordinary achievements. For Polifarma qhis transition is the result of a good job that has involved women and men in recent months, confirming that the company continues to grow with a team vision and aims to always seek new areas of development with determination, adding valid elements for improving people's health”.
WHO IS POLIFARMA
Founded in Italy in 1919, Polifarma is today part of Final SpA, a financial group headed by Mrs. Luisa Angelini. The company is active in the cardiovascular, gastroenterology and system therapeutic areas Central Nervous, Ophthalmology, Infectious Diseases and has been a point of reference for the medical profession for years, being able to count on a network of scientific representatives who contribute to spreading quality, experience and competence. Among the values that characterize the corporate philosophy in the foreground are attention to the person, orientation to results, dynamism, innovation and an ever attentive look at the national and international market. With the birth of the Research and Development division in 2022, Polifarma works to make new bio-digital solutions available to patients all over the world, capable of promoting the maximum benefit from pharmacological therapy enhanced by clinically validated and CE Certified digital solutions. For more information www.polifarma.it And www.polifarmanext.it
Received in the editorial staff on January 12, 2023